Brief: Ascletis Pharma Inc - Denifanstat Meets All Efficacy Endpoints In Phase Iii Trial
14/10/2025 11:24
Oct 14 (Reuters) - Ascletis Pharma Inc 1672.HK: ASCLETIS PHARMA INC - DENIFANSTAT MEETS ALL EFFICACY ENDPOINTS IN PHASE III TRIAL ASCLETIS PHARMA INC - DENIFANSTAT SHOWS FAVORABLE SAFETY WITH MILD OR MODERATE TREATMENT-EMERGENT ADVERSE EVENTS Source text: ID:nPn80byTGa Further company coverage: 1672.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsAscletis hits 4-week high on initiating US Phase I study on obesity drug
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management